Contract analysis

I. Purpose and Overview This memorandum sets forth the comprehensive hearing strategy for the five-day evidentiary hearing scheduled for January 8 through January 12, 2024, at the ICC Hearing Centre, New York, New York. The memorandum is intended to serve as the central strategic reference document for all members of the hearing team and addresses opening statement themes, witness examination order, key documentary e

II. Tribunal Composition and Assessment An accurate assessment of the Tribunal's composition, predispositions, and likely areas of focus is essential to the effective presentation of WAL's case. The following analysis is based on the known professional backgrounds of the three arbitrators, their published writings and decisions (where available), and our experience in prior proceedings involving each of them. A. Pres

1. Tailor presentations to the presiding arbitrator. Prof. Dame Eleanor Fitzwilliam is the likely swing vote on technical credibility issues and will drive the drafting of the award. All presentations should be designed with her priorities in mind: clear contractual language, well-organized documentary evidence, and methodical expert testimony.

2. Ground all arguments in express contractual language. The strongest path to a favorable award runs through the text of the MSA. Textual arguments will resonate with Prof. Dame Eleanor and Judge Castillo. Even Dr. Perren — while potentially sympathetic to good-faith arguments — must acknowledge the primacy of the contractual text under the governing New York law.

3. Anticipate Dr. Perren's civil-law lens. We must prepare thorough responses to questions about proportionality, good faith, and the reasonableness of WAL's conduct. In particular, we must be prepared to address whether WAL's onboarding of Valkyr preceded or followed the quality failures. The timeline evidence is critical on this point, and Gerald Huang must be unshakeable on the chronology during his testimony.

4. Leverage Judge Castillo on legal questions. When presenting legal arguments — particularly on the enforceability of the consequential damages waiver and the standard for expectation damages on unexercised options — we should frame arguments in terms familiar to New York commercial jurisprudence, citing decisions from the New York Court of Appeals and the Southern District.

III. Case Themes for Opening Statement WAL's opening statement will be delivered by Theodore Langston and is estimated at approximately two hours. The opening should be structured around four interlocking themes that collectively present WAL as the party that honored its contractual obligations, was harmed by Kestrel's quality failures, and is now defending against an overreaching damages claim. The themes are design

IV. Witness Examination Order and Schedule A. Proposed Hearing Schedule The following proposed schedule is based on the procedural timetable agreed upon by the parties and confirmed by Procedural Order No. 4, dated November 28, 2023. The schedule reflects the Tribunal's instruction that Claimant present its evidence first, followed by Respondent, with expert testimony grouped on Days 4 and 5 by subject matter. Total

V. Direct Examination Strategy — Respondent's Fact Witnesses A. Gerald Huang — Vice President, Global Supply Chain Operations, WAL Gerald Huang is WAL's primary fact witness and the most important witness in the proceeding. He was the senior WAL executive responsible for managing the procurement relationship with Kestrel under the MSA and was the principal point of contact for all commercial communications with Kestr

1. Overview of WAL's procurement relationship with Kestrel under the MSA. Huang should provide the Tribunal with context regarding the nature of the supply relationship, the types of components procured, the volume of business, and the importance of quality control in the aerospace supply chain. He should explain that titanium alloy turbine housings are safety-critical components subject to rigorous quality standards

2. The lot rejection process. Huang should describe in detail the process by which WAL received, inspected, and either accepted or rejected incoming lots from Kestrel. This process — documented in WAL-QCP-100 — involved receipt of the lot at WAL's Arlington facility, incoming inspection by the quality assurance team under the supervision of Dr. Ingrid Vollmer, issuance of an inspection report, and, in the event of a

3. Specific timeline of the fourteen rejected lots. This is the core of Huang's testimony. He should walk the Tribunal through each of the fourteen rejected lots — identified as Lot KDG-2022-0307 through Lot KDG-2022-0919 — totaling 1,680 units. For each lot, Huang should identify the date of receipt, the date of the rejection notice, the specific non-conformance identified (porosity exceeding ≤0.25% and/or other spe

4. Cure-period communications with Kestrel. Huang should describe his communications with Friedrich Brenner (Managing Director) and Luisa Erdmann (Commercial Director) at Kestrel regarding the cure opportunities provided following each rejection. He should emphasize that WAL provided Kestrel with the full forty-five-day cure period for each rejected lot and that WAL did not cut short the cure period, impose additiona

5. Decision to engage Valkyr Precision Components Inc. This is the most sensitive area of Huang's testimony because it directly addresses the "pretext" narrative. Huang must clearly and convincingly establish that WAL's decision to engage Valkyr as a replacement supplier post-dated the quality failures and was a commercially reasonable mitigation step taken in response to a genuine supply-chain crisis. He should test

6. Counterclaim calculation. Huang should provide the factual basis for WAL's counterclaim of €5.17 million, calculated as follows: 1,680 replacement units × (€8,432.92 – €5,222.92) per-unit premium × 0.958 (reflecting the 4.2% introductory discount) ≈ €5.17 million. Key Documents to Introduce Through This Witness The following documents should be introduced through Gerald Huang's testimony: • Rejection notices for e

1. Timeline of WAL's initial contact with Valkyr. HRS will attempt to establish that WAL initiated contact with Valkyr before the quality failures arose, supporting Kestrel's theory that the termination was a pretext to replace Kestrel with a preferred domestic supplier. Huang must be prepared to address any pre-existing relationship or preliminary contacts with Valkyr and to explain that any such contacts were routi

2. Whether WAL explored competitive bids from other suppliers. HRS will argue that WAL's failure to solicit competitive bids from multiple potential replacement suppliers before engaging Valkyr at premium pricing demonstrates either that the replacement was pre-arranged or that WAL failed to mitigate its damages. Huang should be prepared to testify about the limited universe of qualified suppliers and the urgency of

1. WAL's quality-control inspection process under WAL-QCP-100. Dr. Vollmer should provide the Tribunal with a detailed description of the incoming inspection process, including the personnel involved, the equipment used, the testing protocols applied, and the documentation generated for each inspection. She should establish that the inspection process was standardized, documented, and applied consistently to all inco

2. The porosity specification in WAL-SPEC-TH-401, Appendix C, Table 3. This is the central technical issue in the case. Dr. Vollmer should explain the porosity specification clearly, in terms accessible to a non-technical audience (while remaining technically precise). The contractual limit is ≤0.25% porosity, meaning that the total volume fraction of voids or pores in the cast titanium alloy must not exceed 0.25% of

3. How incoming inspection was conducted. Dr. Vollmer should describe the specific testing methods used, including both standard non-destructive testing (NDT) methods (such as computed tomography scanning and ultrasonic inspection) and metallurgical sampling (destructive testing of sample coupons cut from designated locations within each casting). She should establish that the testing methods used were consistent wit

4. Rebuttal of Kestrel's "unpublished ≤0.15% standard" claim. This is a critical area. Kestrel's central factual theory is that WAL did not actually apply the ≤0.25% contractual standard but instead applied a more stringent, unpublished internal standard of ≤0.15% porosity — effectively tightening the specification without notice to Kestrel. Dr. Vollmer must firmly and credibly rebut this claim. She should testify th

5. Technical justification for each lot rejection. Dr. Vollmer should be prepared to testify about the specific porosity levels measured in each of the fourteen rejected lots. The measured porosity levels ranged from 0.19% to 0.38% across all lots. For lots where the overall range included measurements both above and below 0.25%, Dr. Vollmer should explain that lot-level acceptance requires all sample points within t

6. AS9100 Rev D certification requirements and Kestrel's compliance obligations. Dr. Vollmer should testify about the AS9100 Rev D quality management system certification that Kestrel was required to maintain under the MSA. This certification, issued by Kestrel's certifying body, established minimum quality-management requirements for aerospace suppliers. Dr. Vollmer should be prepared to address whether Kestrel's qu

7. Engineering specifications WAL-SPEC-TH-401 through WAL-SPEC-TH-410. Dr. Vollmer should provide a brief overview of the full suite of engineering specifications governing the turbine housings, including the addition of WAL-SPEC-TH-410 (the high-temperature variant specification) via Amendment No. 1 in February 2020. Key Documents to Introduce Through This Witness • WAL-SPEC-TH-401, including Appendix C, Table 3 (th

1. Internal quality memos referencing a ≤0.15% "target" porosity. HRS will attempt to establish — through internal WAL quality memos obtained during document production — that WAL's engineering department maintained a ≤0.15% porosity "target" that was distinct from the ≤0.25% contractual maximum. HRS will argue that this internal target was the standard actually applied to Kestrel's deliveries, and that lots with por

2. Historical acceptance of lots in the 0.19%–0.25% range. HRS may attempt to establish that in prior contract years, WAL accepted lots from Kestrel (or from other suppliers) with porosity levels in the 0.19%–0.25% range, and that the rejections in 2022 represented a departure from past practice. Preparation Notes. Dr. Vollmer must clearly and consistently distinguish between internal engineering "targets" or "best p

VI. Cross-Examination Strategy — Claimant's Fact Witnesses A. Friedrich Brenner — Managing Director, Kestrel Friedrich Brenner is Kestrel's most senior fact witness and the individual most closely associated with Kestrel's commercial decisions throughout the MSA term. He signed the MSA on behalf of Kestrel, negotiated the terms of both amendments, and was the senior Kestrel executive responsible for the overall comme

1. Establish Brenner's knowledge of the porosity specification. Brenner should be confronted with the porosity specification in WAL-SPEC-TH-401, Appendix C, Table 3 and asked to confirm that he was aware of this specification at the time of MSA execution, that he understood it to be a binding contractual requirement, and that Kestrel agreed to comply with it. This lays the groundwork for the argument that Kestrel can

2. Elicit admissions about Kestrel's internal quality-control difficulties in 2022. Through Brenner's own contemporaneous communications — including emails acknowledging receipt of WAL's rejection notices and Kestrel's internal board minutes discussing quality issues — we should establish that Kestrel was aware of its quality-control problems and was struggling to address them. This undermines the "pretext" narrative

3. Undermine Kestrel's narrative that WAL fabricated quality deficiencies. Brenner should be asked directly whether he believes WAL's rejection notices were fraudulent and whether he has any evidence — beyond the "unpublished ≤0.15% standard" theory — to support such a claim. The goal is to force Brenner to either make an extreme accusation (that WAL fabricated test results) or to retreat to the weaker claim that WAL

4. Probe the negotiation of Amendment No. 2. Amendment No. 2, dated September 3, 2021, extended the cure period from thirty to forty-five calendar days. Brenner should be asked to explain why Kestrel negotiated this extension. The obvious and truthful answer — that Kestrel was having difficulty curing non-conforming deliveries within the original thirty-day period — is an admission that Kestrel was already experienci

1. Challenge the basis for Kestrel's damages claims, particularly the assumed 22.4% margin. Erdmann, as the commercial executive responsible for pricing and margins, should have direct knowledge of Kestrel's actual profitability on the WAL contract. She should be asked to confirm Kestrel's pricing proposals during MSA negotiations, the cost assumptions underlying those proposals, and any internal margin analyses cond

2. Establish that the renewal options were understood by Kestrel to be at WAL's sole discretion. Erdmann should be asked to confirm that the renewal options in the MSA were exercisable by WAL at its sole discretion, that Kestrel had no right to compel renewal, and that Kestrel's own financial planning reflected the discretionary nature of the renewal options. If Kestrel's internal financial projections included a pro

3. Probe whether Kestrel had alternative customers or mitigation opportunities. Erdmann should be asked whether Kestrel sought to market its Ti-6Al-4V ELI turbine housing capabilities to other customers following the termination, whether it had existing relationships with other aerospace companies, and what steps it took to mitigate its alleged losses. Failure to mitigate is a complete or partial defense under New Yo

4. Elicit testimony about pricing proposals. Erdmann's testimony about Kestrel's pricing proposals during MSA negotiations may reveal that Kestrel's actual cost basis and expected margins were different from the figures used by Prof. Langfeld. Any discrepancy between Kestrel's internal expectations and the expert's assumptions is valuable on cross-examination of Prof. Langfeld. Key Document Confrontations • Kestrel's

1. Establish that Dr. Voss was aware of the contractual porosity limit of ≤0.25%. As the head of quality assurance, Dr. Voss should have been intimately familiar with the engineering specifications governing Kestrel's deliveries, including WAL-SPEC-TH-401, Appendix C, Table 3. He should be asked to confirm his awareness of the ≤0.25% limit and to confirm that this was the acceptance/rejection standard he understood t

2. Challenge Dr. Voss's claim that WAL applied an unpublished ≤0.15% standard. Dr. Voss is expected to testify that WAL's rejections were based on an undisclosed internal target of ≤0.15% porosity rather than the contractual ≤0.25% limit. He should be confronted directly with the text of WAL-SPEC-TH-401, Appendix C, Table 3, which states the limit as ≤0.25%, and asked to identify any provision of the MSA, its amendme

3. Probe the adequacy of Kestrel's cure efforts. For each of the uncured rejections, Dr. Voss should be asked what specific cure steps Kestrel undertook, when those steps were initiated, and why the cure was not completed within the forty-five-day amended period. If Kestrel's cure efforts were delayed by internal production constraints, this is an admission that Kestrel's manufacturing processes were inadequate — not

4. Explore AS9100 Rev D certification issues. If Kestrel's AS9100 Rev D certification was the subject of any non-conformance findings, observations, or corrective action requests from its certifying body during the relevant period, this evidence would corroborate WAL's position that Kestrel was experiencing systemic quality issues. Key Document Confrontations • Lot-level porosity test results from Kestrel's own inter

VII. Expert Witness Strategy A. Dr. Raymond Chow — Metallurgical Expert (Arclight Materials Science Inc.) Role and Background Dr. Raymond Chow serves as WAL's independent metallurgical expert. He is a senior materials scientist at Arclight Materials Science Inc. of McLean, Virginia, and holds a Ph.D. in materials science and engineering from Stanford University. He has over fifteen years of experience in the characte

1. Independent testing confirms porosity levels in the 0.19%–0.38% range. Dr. Chow conducted independent metallurgical testing of retained samples from the fourteen rejected lots. His testing confirmed that the porosity levels measured in these lots ranged from 0.19% to 0.38%, with the majority of lots exhibiting porosity levels in excess of the ≤0.25% contractual limit set forth in WAL-SPEC-TH-401, Appendix C, Table

2. The ≤0.25% specification is an industry-standard acceptance criterion. Dr. Chow opines that the ≤0.25% porosity limit for Ti-6Al-4V ELI titanium alloy turbine housings in aerospace applications is consistent with and in many cases less stringent than industry-standard acceptance criteria for comparable components. The specification was not unusual, onerous, or unreasonable.

3. WAL's inspection procedures were consistent with industry practice. Dr. Chow reviewed WAL's incoming inspection procedures under WAL-QCP-100 and opines that they were consistent with industry practice and AS9100 Rev D requirements for incoming material inspection of safety-critical aerospace components.

4. Dr. Kessler's sampling methodology is flawed. In his rebuttal report, Dr. Chow identifies methodological deficiencies in the testing conducted by Kestrel's metallurgical expert, Dr. Martina Kessler of Albrecht Prüftechnik GmbH. Specifically, Dr. Chow opines that Dr. Kessler used a sampling protocol that systematically undersampled high-porosity regions of the castings. By drawing samples predominantly from the gat

1. Qualifications and methodology. Briefly establish Dr. Chow's credentials, expertise, and the methodology he employed in testing the retained samples. The methodology section should be concise but thorough enough to establish that Dr. Chow followed recognized standards for metallurgical testing of aerospace components.

2. Lot-by-lot testing results. Walk Dr. Chow through the testing results for each of the fourteen rejected lots, presenting the porosity data lot-by-lot with a clear visual comparison to the ≤0.25% contractual limit. Use demonstrative exhibits (charts and micrograph images) to make the data accessible to the Tribunal.

3. Explanation of the safety significance of porosity. Have Dr. Chow explain, in terms accessible to a non-specialist audience, why porosity above 0.25% is a safety concern in aerospace turbine housings. The explanation should be clear and vivid without being alarmist — the Tribunal needs to understand that porosity limits are not arbitrary administrative thresholds but reflect genuine engineering requirements relate

4. Rebuttal of Dr. Kessler's opinions. Address Dr. Kessler's rebuttal points directly and methodically. Dr. Chow should explain why Dr. Kessler's sampling protocol was biased, why her lower porosity measurements do not reflect the true condition of the lots, and why his own testing methodology — which sampled from a statistically representative distribution of locations within each casting — is more reliable. Anticip

1. Sample selection. HRS will challenge Dr. Chow's sample selection, arguing that the retained samples he tested were not representative of the lots as a whole or that the chain of custody was inadequate.

2. The 0.19%–0.25% range. HRS will argue that some lots with measured porosity of 0.19%–0.25% technically met the ≤0.25% specification and should not have been rejected. This is a valid point for lots where all sample points fell at or below 0.25%, and Dr. Chow should be prepared to address it candidly. For those lots, the basis for rejection may have been other non-conformances (dimensional tolerances, surface finis

3. Engineering tolerance arguments. HRS will argue that micro-porosity at levels of 0.26%–0.30% — just above the 0.25% threshold — is within acceptable engineering tolerance and does not present a genuine safety risk. Dr. Chow should be prepared to explain that engineering specifications set binary thresholds for a reason: acceptance decisions must be based on objective criteria, not subjective judgments about whethe

1. Kestrel's total damages claim of €47.3 million is grossly overstated. Dr. Ostrovsky has analyzed each component of Kestrel's damages claim and concludes that the claim is inflated, based on unsupported assumptions, and in significant part barred by the express terms of the MSA.

2. Lost profits for the remaining MSA term (€12.83 million). Dr. Ostrovsky opines that this component is barred by the consequential damages waiver in Section 8.7 of the MSA. Even if recoverable, the claimed amount is based on Prof. Langfeld's inflated margin assumption of 22.4%, which is inconsistent with Kestrel's actual financial performance.

3. Lost profits for renewal terms (€27.15 million). Dr. Ostrovsky opines that this component is not recoverable under any analysis. The renewal options were exercisable solely at WAL's discretion under the express terms of the MSA. Kestrel had no expectation interest in the renewal periods, and no prior exercise or pattern of renewal exists to establish a reasonable expectation of renewal. Under New York law, damages

4. Unreimbursed rework costs (€3.42 million). Dr. Ostrovsky acknowledges that a portion of the claimed rework costs may be justified as direct damages, but opines that the claimed amount should be reduced to account for the cost of Kestrel's own defective production. To the extent Kestrel incurred rework costs because it produced non-conforming product, those costs are attributable to Kestrel's own quality failures,

5. Reputational damages (€3.90 million). Dr. Ostrovsky opines that this component is speculative, unsupported by any objective evidence, and barred by Section 8.7. Prof. Langfeld's calculation of reputational damages lacks any recognized economic methodology and is based entirely on conjecture about the impact of the termination on Kestrel's relationships with other customers.

6. Prof. Langfeld's margin assumption is incorrect. Dr. Ostrovsky opines that Prof. Langfeld's assumed margin of 22.4% is inconsistent with Kestrel's actual financial performance as reflected in its financial records. Forensic accounting analysis by Canfield & Thorpe LLP (Sandra Gillespie, CPA/ABV) indicates that Kestrel's true margin on WAL-related products was closer to 14.8%. The difference — more than seven perce

7. WAL's counterclaim of €5.17 million is properly calculated. Dr. Ostrovsky opines that WAL's counterclaim is properly calculated based on the per-unit premium paid to Valkyr (€8,432.92 versus €5,222.92 under Kestrel's CY4 pricing), net of Valkyr's 4.2% introductory discount, across 1,680 replacement units. Direct Examination Strategy The direct examination of Dr. Ostrovsky will be conducted by Theodore Langston and

1. Overview and damages breakdown. Present a clear breakdown of Kestrel's €47.3 million damages claim, identifying each component and its status (barred, overstated, speculative, or potentially valid). Use a demonstrative exhibit — a summary chart — to give the Tribunal a visual roadmap.

2. Consequential damages waiver analysis. Walk Dr. Ostrovsky through her analysis of which components of Kestrel's claim are barred by the consequential damages waiver in Section 8.7. She should explain that lost profits and reputational damages are classic forms of consequential damages that fall squarely within the scope of the waiver.